News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
35,483 Results
Type
Article (2107)
Company Profile (1)
Press Release (33375)
Section
Business (8125)
Career Advice (67)
Deals (1610)
Drug Delivery (7)
Drug Development (7443)
Employer Resources (10)
FDA (1292)
Job Trends (828)
News (18601)
Policy (1827)
Tag
Academia (189)
Allergies (6)
Alliances (1991)
ALS (3)
Alzheimer's disease (112)
Antibody-drug conjugate (ADC) (3)
Approvals (1306)
Artificial intelligence (5)
Autoimmune disease (1)
Bankruptcy (18)
Best Places to Work (694)
Biosimilars (24)
Bladder cancer (2)
Brain cancer (2)
Breast cancer (14)
Cancer (115)
Cardiovascular disease (16)
Career advice (64)
CAR-T (3)
Cell therapy (10)
Cervical cancer (1)
Clinical research (6264)
Collaboration (28)
Compensation (6)
Complete response letters (2)
COVID-19 (174)
C-suite (10)
Cystic fibrosis (4)
Data (213)
Depression (6)
Diabetes (17)
Diagnostics (236)
Digital health (1)
Diversity, equity & inclusion (2)
Drug discovery (7)
Drug pricing (8)
Drug shortages (2)
Duchenne muscular dystrophy (5)
Earnings (3887)
Editorial (2)
Employer branding (1)
Employer resources (9)
Events (4044)
Executive appointments (13)
FDA (1379)
Funding (22)
Gene editing (3)
Generative AI (2)
Gene therapy (17)
GLP-1 (55)
Government (206)
Grass and pollen (1)
Guidances (4)
Healthcare (754)
Huntington's disease (2)
IgA nephropathy (1)
Immunology and inflammation (3)
Infectious disease (180)
Inflammatory bowel disease (10)
Intellectual property (5)
Interviews (7)
IPO (766)
Job creations (164)
Job search strategy (58)
Labor market (1)
Layoffs (28)
Legal (290)
Liver cancer (4)
Lung cancer (21)
Lymphoma (5)
Management (5)
Manufacturing (10)
MASH (2)
Medical device (623)
Medtech (623)
Mergers & acquisitions (864)
Metabolic disorders (48)
Multiple sclerosis (8)
NASH (1)
Neurodegenerative disease (6)
Neuropsychiatric disorders (2)
Neuroscience (156)
NextGen: Class of 2025 (362)
Non-profit (119)
Obesity (25)
Opinion (10)
Ovarian cancer (1)
Pain (37)
Pancreatic cancer (1)
Parkinson's disease (8)
Partnered (2)
Patents (12)
Patient recruitment (7)
Peanut (1)
People (1770)
Pharmaceutical (1)
Pharmacy benefit managers (7)
Phase I (1925)
Phase II (2515)
Phase III (2120)
Pipeline (95)
Policy (1)
Postmarket research (306)
Preclinical (808)
Press Release (2)
Prostate cancer (13)
Psychedelics (2)
Radiopharmaceuticals (7)
Rare diseases (33)
Real estate (208)
Recruiting (4)
Regulatory (1464)
Reports (3)
Research institute (145)
Resumes & cover letters (3)
Rett syndrome (1)
RNA editing (1)
RSV (2)
Schizophrenia (10)
Series A (1)
Series B (1)
Service/supplier (1)
Sickle cell disease (4)
Special edition (1)
Spinal muscular atrophy (6)
Sponsored (2)
Startups (147)
Supply chain (1)
Vaccines (25)
Venture capitalists (1)
Weight loss (13)
Date
Today (8)
Last 7 days (52)
Last 30 days (125)
Last 365 days (1918)
2025 (657)
2024 (1983)
2023 (2246)
2022 (3120)
2021 (3246)
2020 (3176)
2019 (2560)
2018 (1948)
2017 (1897)
2016 (1765)
2015 (2114)
2014 (1414)
2013 (1100)
2012 (1216)
2011 (1258)
2010 (1023)
Location
Africa (38)
Arizona (5)
Arkansas (1)
Asia (2048)
Australia (299)
California (258)
Canada (83)
China (18)
Colorado (14)
Connecticut (9)
Delaware (5)
Europe (5017)
Florida (87)
Georgia (21)
Idaho (3)
Illinois (12)
Indiana (29)
Japan (12)
Kansas (5)
Maine (1)
Maryland (24)
Massachusetts (199)
Michigan (5)
Minnesota (9)
Missouri (4)
Montana (4)
Nebraska (3)
Nevada (2)
New Jersey (201)
New Mexico (1)
New York (86)
North Carolina (49)
North Dakota (1)
Northern California (112)
Ohio (9)
Oregon (1)
Pennsylvania (90)
Puerto Rico (3)
South America (49)
Southern California (104)
Tennessee (6)
Texas (46)
United States (1212)
Utah (16)
Virginia (8)
Washington D.C. (2)
Washington State (12)
35,483 Results for "concentric analgesics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Octapharma USA: JAMA Publishes Results for Investigational Four-Factor Prothrombin Complex Concentrate in Cardiac Surgical Bleeding
April 2, 2025
·
4 min read
Press Releases
A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial
January 1, 2025
·
5 min read
Pain
Tris Pharma Records Late-Stage Win for Non-Opioid Painkiller
Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a significant concern in the analgesic field.
January 22, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Vantage Nutrition to launch groundbreaking higher concentration VitaCholine® into liquid capsules
October 30, 2024
·
1 min read
Pharm Country
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
NanoViricides, Inc. reports that its clinical stage lead nanoviricide broad-spectrum antiviral drug candidate, NV-387, results in an ideal flat blood concentration profile for an extended time period upon oral administration in two different animal models.
June 11, 2024
·
9 min read
Pharm Country
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides, Inc. reports on the highly desirable blood concentration profile of its lead clinical stage broad-spectrum antiviral agent NV-387 upon intravenous administration in a non-human primate animal model.
June 4, 2024
·
8 min read
Drug Development
Concentric Analgesics Forges Important Phase 3 Clinical Relationships for Vocacapsaicin, a Non-Opioid Pain Therapy Targeting TRPV1 Receptor
Concentric Analgesics, Inc today announced two important Phase 3 clinical relationships for its lead product candidate, vocacapsaicin.
February 2, 2022
·
5 min read
Press Releases
Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
November 12, 2024
·
3 min read
Press Releases
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort
-Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration
April 9, 2025
·
4 min read
Drug Development
Concentric Analgesics Announces Positive Results from Pilot Phase 2 Clinical Trial of Vocacapsaicin in Open Laparotomy for Repair of Abdominal Ventral Hernia
Concentric Analgesics, Inc. today announced positive results from its recently completed pilot Phase 2 clinical trial of vocacapsaicin in patients undergoing open laparotomy for ventral hernia repair.
March 30, 2022
·
5 min read
1 of 3,549
Next
